Hurdles imposed by payers and high drug costs present increasing barriers to technological and precision medicine advancements in cancer programs, according to a recent survey by the Association of Community Cancer Centers.
February 2 2019
Robert L. Ferris, MD, PhD, co-physician editor in chief of Targeted Therapies in Oncology, discusses exciting new findings and merit highlights reported in this month's issue.
Presentations at the 60th American Society of Hematology Annual Meeting & Exposition were dominated by advancements in the treatment of chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5